Suppr超能文献

弥漫性大 B 细胞淋巴瘤呈滤泡间生长模式者具有良好的预后:一项来自大阪淋巴瘤研究组的研究。

Diffuse large B cell lymphoma with an interfollicular pattern of proliferation shows a favourable prognosis: a study of the Osaka Lymphoma Study Group.

机构信息

Department of Pathology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.

出版信息

Histopathology. 2012 May;60(6):924-32. doi: 10.1111/j.1365-2559.2011.04161.x. Epub 2012 Feb 9.

Abstract

AIMS

Diffuse large B cell lymphoma (DLBCL) occasionally shows an interfollicular pattern of proliferation (DLBCL-IF) preserving lymphoid follicles. In this study, clinicopathological findings in 31 cases of DLBCL-IF were analysed.

METHODS AND RESULTS

The study group comprised 20 males and 11 females, with ages ranging from 41 to 87 (median 69) years. The primary site was lymph node in 25 cases, and unknown in six due to advanced stage at diagnosis. Eight cases were clinical Stage I, 10 were Stage II, four Stage III, and nine Stage IV. A polymorphous pattern of proliferation containing large B cells and inflammatory cells was found in about 60% of cases. The overall survival rate of the DLBCL-IF patients was better than that of a DLBCL control group (log-rank test; P < 0.05). Multivariate analysis revealed that an interfollicular pattern of proliferation showed marginal significance for favourable prognosis (P = 0.069). Immunohistochemical double staining with antibodies for HLA-DR/CD68 (markers for M1-tumour-associated macrophage [M1-TAM]) or CD163/CD68 (M2-TAM) revealed that all DLBCL-IF patients with a low M2 count were alive at the end of observation.

CONCLUSIONS

These findings suggest that DLBCL-IF is a clinicopathological entity distinct from ordinary DLBCL. The possible origin of tumour cells in DLBCL-IF from marginal zone B cells is discussed.

摘要

目的

弥漫性大 B 细胞淋巴瘤(DLBCL)偶尔表现为保留淋巴滤泡的滤泡间增生模式(DLBCL-IF)。本研究分析了 31 例 DLBCL-IF 的临床病理特征。

方法和结果

研究组包括 20 例男性和 11 例女性,年龄 41-87 岁(中位年龄 69 岁)。25 例原发部位为淋巴结,6 例因诊断时处于晚期而原发部位不明。8 例为临床Ⅰ期,10 例为Ⅱ期,4 例为Ⅲ期,9 例为Ⅳ期。约 60%的病例存在大 B 细胞和炎症细胞的多形性增生模式。DLBCL-IF 患者的总生存率优于 DLBCL 对照组(对数秩检验;P < 0.05)。多因素分析显示,滤泡间增生模式对预后有一定的提示作用(P = 0.069)。用 HLA-DR/CD68(M1 肿瘤相关巨噬细胞[M1-TAM]标志物)或 CD163/CD68(M2-TAM)进行免疫组化双重染色,结果显示所有 M2 计数低的 DLBCL-IF 患者在观察结束时均存活。

结论

这些发现表明,DLBCL-IF 是一种与普通 DLBCL 不同的临床病理实体。讨论了 DLBCL-IF 肿瘤细胞来源于边缘区 B 细胞的可能性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验